Overview of Aphenylbarbit

Property	Description
Active ingredient	Phenobarbital
Form	Tablet, oral solution, solution for injection
Pharmacological class	Long-acting Barbiturate, Central Nervous System (CNS) Depressant
General purpose	To stabilize nerve excitability and provide foundational sedation
Origin	Synthetic (Barbituric acid derivative)

What Type of Medicine is Aphenylbarbit (Phenobarbital)?

Aphenylbarbit is a prescription medicinal product containing the single active ingredient, Phenobarbital, a synthetic compound derived from barbituric acid. The medicine is definitively classified as a long-acting barbiturate and a potent Central Nervous System (CNS) depressant. This classification is clinically recognized for providing sustained control over neuronal activity.

Phenobarbital holds a distinctive position among CNS depressants because of its lengthy half-life, a characteristic that supports its use in scenarios requiring consistent, around-the-clock control. This sustained duration of action is a primary differentiating factor when compared to other agents in the barbiturate class. The drug is recognized for its foundational therapeutic status, which is reflected by its inclusion on the global Model List of Essential Medicines.

Composition and Available Forms of Aphenylbarbit

The composition of Aphenylbarbit is monocomponent, focusing entirely on Phenobarbital (5-ethyl-5-phenylbarbituric acid) without combining it with other active pharmaceutical ingredients. The drug is supplied in various presentations to ensure effective delivery.

These include solid oral preparations (such as tablets and capsules) and liquid preparations, including oral solutions and elixirs. Critically, it is also prepared as a sterile solution for injection allowing for parenteral administration (intravenous or intramuscular). The availability of an oral solution is a practical feature, ensuring precise dose measurement for patient groups, such as the pediatric population.

What is the General Purpose of Phenobarbital's Action?

The general purpose of this medicine is to stabilize and calm an overactive nervous system by broadly reducing nerve cell excitability. This foundational action is used to mitigate states of neuronal hyperexcitability and to achieve a controlled state of sedation.

Phenobarbital's mechanism effectively enhances the inhibitory effects of GABA, the brain's main calming neurotransmitter. This confirms the medicine's role in dampening the electrical signals in nerve cells. The overall benefit is the reliable management of abnormal neuronal firing, leading to the maintenance of sustained neurological stability.

Regulatory References

What side effects are possible with Aphenylbarbit?

Possible side effects and safety information

The safety profile of Aphenylbarbit (Phenobarbital) reflects its classification as a potent Central Nervous System (CNS) depressant, with adverse effects formally organized by frequency, affected system, and potential seriousness in regulatory documents.

Adverse effects relating to CNS depression, such as somnolence (drowsiness), ataxia, and nystagmus, are officially documented as common and are often more pronounced during the initial phase of treatment or following a dose increase. This pattern is noted across official prescribing information.

Serious adverse reactions are documented in official labeling, including the potential for life-threatening Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The risk for these reactions is documented as being highest during the first few weeks of therapy.

Specific population-related safety considerations are mandated by regulators. In pediatric patients, the drug may uncommonly cause paradoxical excitement or hyperactivity. For older adults, there is an officially noted increased risk of confusion and adverse CNS effects due to slower clearance. Furthermore, the medicine is formally contraindicated in patients with conditions such as acute porphyrias or severe hepatic impairment. Long-term use is associated with the risk of developing physical dependence, as well as hematological effects like megaloblastic anemia and musculoskeletal effects like osteomalacia.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information emphasizes that Aphenylbarbit (Phenobarbital) overdose poses a serious and potentially life-threatening risk, with fatalities documented in severe cases.

Documented Overdose Manifestations

System	Manifestation or Outcome
Central Nervous System (CNS)	Comatose state, depression of reflex activity, positive Babinski sign, EEG of the “burst-suppression” type, moderate intoxication resembling alcoholic inebriation.
Cardiorespiratory	Apnea, respiratory depression, Cheyne-Stokes rhythm, profound hypotension, and circulatory collapse.

Required Emergency Action

Immediate medical attention is required when overdose is suspected, due to the critical risk of apnea and circulatory collapse. The official management strategy is based on symptomatic and supportive therapy, as no specific antidote is known for Phenobarbital poisoning. Supportive measures, which must be performed by medical professionals, may include gastric lavage, administration of intravenous fluids, maintenance of blood pressure, and ensuring adequate respiratory exchange. Advanced procedures like dialysis may be required to enhance drug removal in severe cases. These actions are mandated to manage the core toxic effects of profound CNS depression and resulting cardiorespiratory system failure.

Therapeutic Uses of Aphenylbarbit

Aphenylbarbit is an established treatment utilized in the mathbfmanagement mathbfof mathbfseizures mathbfand mathbfepilepsy. Its primary role is to mathbfhelp mathbfreduce the frequency and severity of certain seizure types, including generalized tonic-clonic and focal impaired awareness seizures. This medication may also mathbfserve mathbfas mathbfan mathbfaid mathbfin mathbfthe mathbfshort-mathbfterm mathbfrelief of mathbfanxiety and mathbfnervousness. It is sometimes mathbfconsidered mathbffor mathbfuse mathbfin mathbfmanaging withdrawal symptoms in patients with dependence on certain other sedatives, due to its properties that mathbfassist mathbfin mathbfcalming mathbfoveractivity in the central nervous system.

Quick Fact: Relief for Seizures

Clinical scenarios where Aphenylbarbit may be part of the care plan involve the need to mathbfmanage seizure activity in various populations, including use in young children, as well as providing mathbfsupport mathbfduring mathbfperiods mathbfof mathbfsedation required for certain medical procedures. The benefits offered center on providing a mathbfstabilizing mathbfeffect on the central nervous system, which mathbfcontributes mathbfto mathbfsymptom mathbfcontrol in the indicated conditions, such as: tonic-clonic seizures, focal onset seizures, and managing excessive anxiety.

“The goal of treatment is to support the patient's stability and assist in the reduction of symptom burden.”

Regulatory References

NIH MedlinePlus drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Aphenylbarbit (Phenobarbital)?

Regulatory authorities define strict population eligibility for Aphenylbarbit, a medicine containing Phenobarbital. Use is generally established for adults and pediatric patients for certain approved conditions.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used in individuals with:

A known hypersensitivity or allergy to barbiturates.
A history of acute intermittent porphyria.
Severe respiratory depression or marked pulmonary insufficiency.
Marked impairment of liver function (severe hepatic impairment).
Hyperkinetic children.

Restricted and Conditional Use

Use is highly restricted and requires caution in several populations:

Organ Impairment: Patients with mild to moderate renal or hepatic impairment require dose adjustment and close monitoring.
Age: Older adults require lower starting doses due to increased sensitivity.
Pregnancy and Lactation: Use is not recommended during pregnancy (Pregnancy Category D) due to fetal risk, and it is not recommended for breastfeeding mothers, as the substance passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aphenylbarbit (Phenobarbital) is officially documented to participate in numerous interactions, primarily due to its role as a potent inducer of hepatic microsomal enzymes, leading to increased metabolism of co-administered agents. This induction reduces the plasma concentrations and therapeutic effect of many medicines. Additionally, the drug has additive effects with other Central Nervous System (CNS) depressants.

Clinically Significant Interactions

Mechanism/Effect	Interacting Product Categories (Examples)	Constraint/Resulting Requirement
Enzyme Induction (Decreased Efficacy)	Oral Anticoagulants (warfarin), Corticosteroids, Doxycycline, Hormonal Contraceptives (estradiol)	Decreased efficacy of co-administered drug, requiring close monitoring and potential dosage adjustment. For hormonal contraceptives, reduced effectiveness necessitates an alternate method.
Additive CNS Depression (PD)	Alcohol, Sedatives, Hypnotics, Tranquilizers	Increased risk of enhanced depressant effects, including sedation.
Altered Aphenylbarbit Levels	Valproic Acid, Sodium Valproate, MAOIs	May increase Aphenylbarbit's plasma concentration, requiring therapeutic drug monitoring.

General Considerations

The co-administration of oral contraceptives with Aphenylbarbit may result in contraceptive failure due to enhanced hormone metabolism. Patients stabilized on medicines sensitive to enzyme induction, such as oral anticoagulants, must have their therapeutic response closely monitored upon the initiation or discontinuation of Aphenylbarbit. This interaction profile defines constraints for co-administration across various pharmacological classes.

Mechanism of Action

Aphenylbarbit is an umbrella term sometimes used for the barbiturate class of central nervous system (CNS) depressants, with Phenobarbital being the primary active compound. Its mechanism of action involves multiple pathways in the brain that collectively lead to a net inhibition of neuronal activity.

Enhancement of Inhibitory GABA Signaling

This domain focuses on the drug's primary action at the gamma-aminobutyric acid type A (GABAA) receptor, which is the main inhibitory neurotransmitter receptor in the CNS. The drug acts as an allosteric modulator, prolonging the duration of the opening of the receptor's associated chloride ion channel. This action increases the influx of negative chloride ions, causing a sustained hyperpolarization of the neuronal membrane and making the neuron significantly less responsive to excitatory stimuli, resulting in a net reduction of neuronal excitability.

Modulation of Excitatory Neurotransmission

Beyond boosting inhibitory pathways, the drug engages mechanisms to directly counteract CNS excitation. This involves the inhibition of calcium channels and the blockade of excitatory glutamate-induced depolarizations via AMPA/Kainate receptors. By modifying these early molecular steps, the drug decreases the release of excitatory neurotransmitters and raises the threshold for generating an action potential, influencing feedback regulation within targeted neural circuits.

Dosage and Administration Information

How to Use Aphenylbarbit

Aphenylbarbit, which contains phenobarbital, is administered through specific routes and schedules as outlined in official prescribing information. The medicine is available in several forms, including oral tablets and elixirs for routine management, and as a solution for injection (intramuscular or intravenous) for acute or specialized situations. The oral route is the primary method for long-term therapy.

Dosing and Administration Protocols

Official instructions define precise dosing ranges that depend on the specific usage pattern. For adult anticonvulsant maintenance, the typical daily dose is between 60 mg and 200 mg. This maintenance dose is usually taken once daily or may be divided into two or three administrations. For urgent needs, such as status epilepticus, the medicine is administered intravenously as a single loading dose of 15 to 20 mg/kg.

Intravenous administration mandates strict controls: the infusion rate must be slow, generally not exceeding 60 mg per minute in adults, and requires close medical supervision. Furthermore, the injectable solution may require reconstitution or dilution prior to use.

Population-Specific Instructions and Tapering

Official guidance requires dose modification for certain populations. The dose must be reduced for older adults and for patients with known hepatic or renal impairment due to the body’s altered ability to process the drug. When long-term therapy is concluding, the medicine must never be stopped abruptly. Instead, the official protocol requires a gradual reduction, or dose tapering, to maintain patient stability and prevent adverse events associated with sudden withdrawal. If a regular oral dose is missed, official instructions specify skipping the missed dose and resuming the normal schedule, with a prohibition on taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aphenylbarbit

Evidence for Use in Conditions such as Seizures and Epilepsy

Research into Aphenylbarbit for conditions such as seizures and epilepsy is supported by long-standing clinical and pharmacological studies leading to its inclusion in therapeutic guidelines. Studies examined outcomes related to seizure frequency and severity for generalized tonic-clonic and focal impaired awareness seizures. Research monitors the assessment of neurological stability over typically long-term assessment periods, which was a factor in its inclusion on the WHO Model List of Essential Medicines.

Evidence for Use in Contexts of Short-Term Anxiety and Nervousness

The evidence base for use in contexts of short-term anxiety relies on pharmacological studies and research exploring short-term symptom changes. Studies monitored outcomes related to perceived discomfort and outcomes describing episodic or acute changes. Research has explored its profile in conditions associated with acute or disruptive episodes, with observation periods generally short-term.

Evidence for Use in Conditions such as Sedative Withdrawal

For conditions such as sedative withdrawal, research was evaluated in scenarios involving periods of heightened symptom activity and temporary physiological imbalance. Studies explored outcomes related to symptom control during this acute phase. Evidence describes patterns where the medicine was studied for its use in contexts involving overactivity, contributing to the broader evidence landscape regarding acute symptom activity.

Studies in Special Populations

Research has focused on assessing the use of Aphenylbarbit in various patient populations, including evaluating outcomes in the pediatric population and young children for seizure research. These specialized studies describe patterns related to how patients reported their experience in these specific age groups. Data for other subgroups may have limited information for long-term outcomes.

Long-Term Evidence and Durability of Response

Studies involving Aphenylbarbit have been conducted over different follow-up durations depending on the context it was studied for. Long-term follow-up is used to monitor the assessment of neurological stability in epilepsy. However, observation periods for acute uses were limited to short-term periods. Long-term effects are not fully established for all therapeutic applications.

Research Gaps and What Remains Uncertain

The evidence landscape always presents areas for further research. Long-term effects are not fully established for every patient group or every indication. Research often does not include direct comparisons with certain other available therapeutic options. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns; therefore, research does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aphenylbarbit (FAQ)

Q: How quickly does Aphenylbarbit start working after I take it?

Official prescribing information indicates that the onset of action for the oral form of Phenobarbital (Aphenylbarbit) generally begins within 30 minutes. This timeframe is consistent with its function as a central nervous system depressant.

Q: Can taking Aphenylbarbit affect my ability to drive or operate machinery?

Yes. Regulatory warnings state that individuals should be cautious about driving a car or operating heavy machinery until they know how this medication affects them. This is due to its potential to cause central nervous system (CNS) depression.

Q: Is it normal to feel a little 'out of it' or dizzy when starting Aphenylbarbit?

Dizziness and a feeling of confusion are listed in regulatory patient information as potential side effects. These effects are often associated with the medication’s action as a CNS depressant and may be more noticeable when treatment is initiated.

Q: How long does Aphenylbarbit stay in your system?

Phenobarbital is known for its long half-life, meaning its effects are sustained. It is processed in the liver, and the body eliminates a significant portion of the dose (25% to 50%) through the kidneys without first breaking it down.

Q: Are there any specific foods or drinks I need to avoid while on Aphenylbarbit?

Regulatory warnings indicate that concurrent use of alcohol should be avoided due to the significant risk of enhanced central nervous system (CNS) depressant effects. This combination can lead to excessive sedation.

Q: Can Aphenylbarbit interact with over-the-counter pain relievers like ibuprofen?

Aphenylbarbit is a potent enzyme inducer, meaning it can speed up the way the liver metabolizes many other medications. While specific over-the-counter products are not always listed, regulatory information advises informing healthcare providers of all co-administered medications.

Q: Is Aphenylbarbit effective for treating anxiety?

The medication is officially indicated for use as a sedative, and the barbiturate class is historically used for its properties in relieving anxiety. Its primary purpose is to stabilize and calm an overactive nervous system.

Q: What should pregnant or breastfeeding women know about Aphenylbarbit?

The medication is classified as Pregnancy Category D, indicating evidence of fetal risk. For breastfeeding mothers, the active ingredient is known to pass into breast milk. Regulatory information states this may potentially cause adverse effects in the infant, such as drowsiness or poor weight gain, and use is generally not recommended.

Q: Does Aphenylbarbit affect my sleep patterns?

Yes. Aphenylbarbit is classified as a sedative-hypnotic, and a common side effect is somnolence, or drowsiness. The drug directly influences the sleep-wake cycle as part of its action to depress the central nervous system.

Q: Does Aphenylbarbit affect laboratory test results?

Official regulatory information documents that Phenobarbital can interfere with certain laboratory tests. This includes potentially elevating liver enzyme levels and affecting the results of certain thyroid function testing.

Q: Are there any known withdrawal symptoms associated with stopping Aphenylbarbit?

Regulatory warnings state that abrupt discontinuation of Aphenylbarbit can lead to severe, potentially life-threatening acute withdrawal reactions. For this reason, the drug must always be gradually tapered (reduced) under medical supervision.

Q: Does Aphenylbarbit have different uses at different doses?

Yes, official regulatory dosing information specifies different dose ranges for different therapeutic goals. For example, the dose required for use as a sedative is distinct from the dose used for long-term anticonvulsant treatment.

Q: Is Aphenylbarbit appropriate for children's use?

Phenobarbital is approved for use in pediatric patients for seizure disorders. However, it is officially contraindicated in hyperkinetic children and may cause a paradoxical side effect of excitement or hyperactivity in some children.

Q: Can Aphenylbarbit interact with herbal supplements like St. John's Wort?

Official guidance notes that St. John's Wort may interact with Aphenylbarbit. This combination may increase the risk of central nervous system (CNS) side effects, such as drowsiness, confusion, and dizziness.

Q: Do I need any special monitoring or blood tests while on Aphenylbarbit?

Yes, therapeutic drug monitoring (TDM) is often required, particularly to check the concentration of the drug in the blood. Monitoring may also be done to check for potential liver function changes.

Q: Is there a generic version of Aphenylbarbit available?

Yes. While Aphenylbarbit may be an umbrella term, its active ingredient, Phenobarbital, is a foundational drug that has been widely available in generic form for many decades.

Q: Can Aphenylbarbit interact with medicines for high blood pressure?

Yes. Because Aphenylbarbit is a strong enzyme inducer, it can speed up the breakdown of various medications, including certain drugs used to treat high blood pressure (such as Felodipine or Eplerenone). This interaction can potentially reduce the effectiveness of the blood pressure medicine.

Q: How is Aphenylbarbit eliminated from the body?

The body processes Aphenylbarbit through two systems. It is metabolized, or broken down, by enzymes in the liver. The resulting compounds are then primarily eliminated from the body by excretion through the kidneys (in the urine).

Q: Can Aphenylbarbit worsen symptoms of depression?

Official warnings state that Phenobarbital use may cause or worsen symptoms of mental depression. Regulatory documents also include associations with suicidal behavior and ideation.

Q: Is it possible to develop a tolerance to the effects of Aphenylbarbit?

Yes. Regulatory warnings state that tolerance to the sedative and hypnotic effects of Phenobarbital may develop with continued, prolonged use. This risk is related to its potential for causing physical and psychological dependence.

Q: Does Aphenylbarbit interact with supplements like melatonin?

Official guidance suggests that the co-administration of Phenobarbital with melatonin may increase the risk of central nervous system (CNS) side effects. This combination could lead to increased drowsiness or dizziness.

Q: What should I do if I accidentally take two doses of Aphenylbarbit close together?

Accidental intake of more than the prescribed dose may lead to symptoms of overdose, such as uncoordinated movement (ataxia), extreme lethargy, or even coma. If a double dose is accidentally taken or an overdose is suspected, it is critical to seek immediate emergency medical care.

How should Aphenylbarbit be stored and disposed of?

Storage Requirements

Phenobarbital (Aphenylbarbit) must be stored under Controlled Room Temperature, defined as 20^circ to 25^circC (68^circ to 77^circF). The regulatory labeling requires the medication to be protected from excessive heat, light, and moisture. To maintain product stability, it must be kept in a tight, light-resistant container. Due to the medication's nature, all forms must be stored strictly out of the reach of children, and the container must feature a child-resistant closure.

Official Disposal Instructions

As Phenobarbital is classified as a Schedule IV Controlled Substance, disposal must follow specific federal guidelines. The preferred method for discarding unused or expired product is through an authorized Drug Take-Back Program or official collector. If no such program is readily available, the medicine may be mixed with an undesirable substance (such as coffee grounds) and sealed in a bag for disposal in the household trash, following established regulatory protocols.

Aphenylbarbit